A Narrative Review; Relation of Coronavirus Disease 2019 (COVID-19) with Several Hematological Disorders
Open Access
- 19 August 2024
- journal article
- review article
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 19 (4)
Abstract
Context: It's crucial to monitor hematologic biomarkers in patients with coronavirus disease 2019 (COVID-19) to identify abnormalities and guide treatment decisions. These biomarkers provide valuable information about the severity of the disease and assist healthcare providers in making informed decisions about patient care. Evidence Acquisition: The present study reviewed the most recent literature on hematologic biomarker abnormalities in patients with COVID-19 and considered their clinical significance. Results: Various abnormalities were observed in hematologic biomarkers, including prothrombin time (PT), partial thromboplastin time (PTT), red blood cell indices, interferon regulatory factor (IRF-7), and white blood cell (WBC) count. Notably, significant lymphocytopenia, thrombocytopenia, and leukocytosis were reported in patients with severe and fatal COVID-19 compared to those with non-severe disease and survivors. Conclusions: Hematologic biomarkers play a crucial role in understanding COVID-19 pathogenesis and guiding clinical management. Utilizing these markers allows clinicians to assess disease severity, predict prognosis, and tailor treatment strategies to improve patient outcomes. Continued research in this area is essential to fully realize the potential of hematologic biomarkers for COVID-19 management.Keywords
This publication has 31 references indexed in Scilit:
- COVID-19 diagnosis by routine blood tests using machine learningScientific Reports, 2021
- Hematologic disorders associated with COVID-19: a reviewAnnals of Hematology, 2021
- COVID-19 versus HIT hypercoagulabilityThrombosis Research, 2020
- COVID-19: Review and hematologic impactClinica Chimica Acta, 2020
- Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19Respiratory Medicine Case Reports, 2020
- mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19Gene Reports, 2020
- Biomarkers associated with COVID-19 disease progressionCritical Reviews in Clinical Laboratory Sciences, 2020
- Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patientsDiabetes Research and Clinical Practice, 2020
- Lymphopenia in COVID‐19: Therapeutic opportunitiesCell Biology International, 2020
- Factors determining the appearance of glucose in upper and lower respiratory tract secretionsIntensive Care Medicine, 2003